Fc-acylated polypeptide conjugate
Fc-acylated polypeptide conjugates address the inconvenience of frequent injections in Type 2 diabetes therapy by extending the duration of action, enhancing treatment efficacy and adherence.
JP2026143441APending Publication Date: 2026-09-08ELI LILLY & CO
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2026081184
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-07-24
- Filing Date
- 2026-05-13
- Publication Date
- 2026-09-08
AI Technical Summary
Technical Problem
Current injectable incretin-based therapies for Type 2 diabetes mellitus require frequent administration, which can be inconvenient and may affect patient adherence and treatment success.
Method used
Development of Fc-acylated polypeptide conjugates that extend the duration of action by conjugating therapeutic polypeptides like GIP, GLP-1, and glucagon to an antibody's Fc region via linkers, enhancing pharmacokinetic and pharmacodynamic profiles.
Benefits of technology
The Fc-acylated polypeptide conjugates provide a longer duration of therapeutic effect, potentially reducing administration frequency and improving patient adherence and treatment outcomes.
✦ Generated by Eureka AI based on patent content.
Abstract
This provides compounds for managing type 2 diabetes. [Solution] A compound is provided comprising a therapeutic polypeptide Fc conjugate having activity in one or more of the following: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and / or glucagon (GCG) receptors. These compounds have structural features that induce activity in one or more of these receptors and extend the duration of action. Methods for treating diseases and / or conditions such as obesity, chronic weight management, and type 2 diabetes are also provided.
Need to check novelty before this filing date? Find Prior Art